E-LIB Suche - Ergebnisse für: Dapavo, P.

1

P973 Real-world data on the effectiveness on IBD of anti-IL..:

Ribaldone, D G ; Palumbo, A ; Cariti, C...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1765-i1765 , 2024

Link: https://doi.org/10.1093/..

2

Effectiveness of guselkumab in patients with facial and/or ..:

Bonifati, C. ; Lembo, S. ; Richetta, A. G....
Journal of the European Academy of Dermatology and Venereology. , 2024

Link: https://doi.org/10.1111/..

3

Long‐term effectiveness and tolerability of apremilast in p..:

Gargiulo, L. ; Ibba, L. ; Malagoli, P....
Journal of the European Academy of Dermatology and Venereology. , 2024

Link: https://doi.org/10.1111/..

4

'Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab fai..:

Mastorino, L. ; Ortoncelli, M. ; Dapavo, P...
Journal of the European Academy of Dermatology and Venereology. 38 (2023) 2 - p. , 2023

Link: https://doi.org/10.1111/..

5

A risankizumab super responder profile identified by long‐t..:

Gargiulo, L. ; Ibba, L. ; Malagoli, P....
Journal of the European Academy of Dermatology and Venereology. 38 (2023) 1 - p. , 2023

Link: https://doi.org/10.1111/..

6

Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab fail..:

Mastorino, L. ; Susca, S. ; Cariti, C....
Journal of the European Academy of Dermatology and Venereology. 37 (2023) 9 - p. 1848-1853 , 2023

Link: https://doi.org/10.1111/..

7

Impact of comorbidities in elderly and frail patients and r..:

Rosset, F. ; Mastorino, L. ; Dapavo, P...
Experimental Dermatology. 32 (2023) 7 - p. 1162-1164 , 2023

Link: https://doi.org/10.1111/..

8

Drug survival, effectiveness and safety of ixekizumab for m..:

Mastorino, L. ; Dapavo, P. ; Burzi, L....
Journal of the European Academy of Dermatology and Venereology. 38 (2023) 3 - p. 568-575 , 2023

Link: https://doi.org/10.1111/..

9

Risankizumab shows faster response in bio naïve than in bio..:

Mastorino, L. ; Castelli, F. ; Stroppiana, E....
Journal of the European Academy of Dermatology and Venereology. 36 (2022) 10 - p. , 2022

Link: https://doi.org/10.1111/..

10

Real‐life comparison between secukinumab and ixekizumab in ..:

Avallone, G. ; Cariti, C. ; Dapavo, P....
Journal of the European Academy of Dermatology and Venereology. 36 (2022) 7 - p. , 2022

Link: https://doi.org/10.1111/..

11

Comparison of Secukinumab and Ixekizumab in psoriasis: a re..:

Cariti, C. ; Dapavo, P. ; Mastorino, L....
Journal of the European Academy of Dermatology and Venereology. 36 (2021) 3 - p. , 2021

Link: https://doi.org/10.1111/..

12

Effectiveness of Secukinumab in the treatment of moderate–s..:

Ribero, S. ; Ramondetta, A. ; Fabbrocini, G....
Journal of the European Academy of Dermatology and Venereology. 35 (2021) 7 - p. , 2021

Link: https://doi.org/10.1111/..

13

Atopic dermatitis, dupilumab and cancers: a case series:

Siliquini, N. ; Giura, M.T. ; Viola, R....
Journal of the European Academy of Dermatology and Venereology. 35 (2021) 10 - p. , 2021

Link: https://doi.org/10.1111/..

14

The impact of theCOVID‐19 pandemic on patients with chronic..:

Gisondi, P. ; Facheris, P. ; Dapavo, P....
British Journal of Dermatology. 183 (2020) 2 - p. 373-374 , 2020

Link: https://doi.org/10.1111/..

15

Evidence for a 'window of opportunity' in hidradenitis supp..:

Marzano, A.V. ; Genovese, G. ; Casazza, G....
British Journal of Dermatology. 184 (2020) 1 - p. 133-140 , 2020

Link: https://doi.org/10.1111/..